Suchergebnisse

Overseas, government payers challenge biopharma companies to show evidence of cost-effectivess. Collaboration there could provide a model for U.S. payers and manufacturers.

As healthcare costs rise in the United States, debate is ongoing over how to obtain better value for dollars spent. In this context, the use of cost-effectiveness analysis (CEA) is more compelling than ever. This work, written by the Second Panel on Cost-Effectiveness in Health and Medicine, reviews key concepts and analytic challenges in CEA. The authors endorse the original panel's concept of a reference case and support its recommendation that analysts take a broad societal perspective; in addition, they recommend a healthcare sector perspective for a second reference case, as well as an important new framework, the Impact Inventory, for detailing costs and effects.

AbstractCost‐benefit and cost‐effectiveness analyses have not been used extensively in program evaluation, despite their obvious value when public and private resources are limited and several courses of action are feasible. Future developments in this area will require consideration of multiple objectives, limited information, and lack of proficiency of decision makers in the use of these techniques.